Introduction {#S0001}
============

Crohn\'s disease (CD) is a chronic and disabling inflammatory disease of the digestive tract of unknown etiology. It may affect any part of the gastrointestinal tract from the mouth to the anus, but most commonly the terminal ileum or the ileocecal region is affected. The highest incidence of ulcerative colitis and CD has been reported in: Northern Europe, the United Kingdom and North America \[[@CIT0001]\]. The etiology of CD remains unknown, but the characteristic disproportionate inflammatory response in the gut may develop through various mechanisms at the cellular and subcellular level \[[@CIT0001]\]. Current medical treatment of CD, besides conventional therapy such as sulfasalazine, 5-aminosalicylates, corticosteroids and immunomodulators, include biological therapy \[[@CIT0002]\]. Tumor necrosis factor (TNF) α is a crucial mediator of the abnormal immune response in the gut and in recent years, biological therapies targeting TNF-α have significantly improved the management of CD refractory to conventional therapies \[[@CIT0003]\]. Infliximab, adalimumab and certolizumab pegol are anti-TNF-α antibodies approved for the treatment of CD.

The aim of this systematic review with meta-analysis was to assess the effectiveness and safety of infliximab, adalimumab and certolizumab when compared with placebo (or each other) for induction and maintenance treatment, as well as fistula closure in adults with Crohn\'s disease.

Material and methods {#S0002}
====================

This meta-analysis included all parallel randomized or clinical controlled trials (CCTs) comparing infliximab, adalimumab or certolizumab in any dosage/treatment regimen with placebo or each other. The studies included had to be performed with a control group but not necessarily with random allocation and/or blinding. Articles published as a full text were preferable because of the opportunity to verify the reliability or potential usefulness of the studies (availability of the full text of primary studies allows an accurate assessment of their quality and also provides essential information about the study population, applied treatment regimen and specific data to extract), but unpublished ones were also taken into consideration. The participants in these studies were adults (≥ 18 years old) with moderate to severe, as well as fistulizing, active CD. Studies concerning combination therapy in comparison with monotherapy or surgical intervention, or comparing different dosage/treatment regimens of the same drug, were excluded.

In order to find the primary studies, the following electronic databases were searched up to November 2012: MEDLINE via PubMed, EMBASE and the Cochrane Central Register of Controlled Trials. Searches for primary studies were also restricted and based on appropriate MeSH and EMTREE terms that meet the requirements: Crohn\'s disease and the intervention infliximab, adalimumab or certolizumab, combined with Boole\'s logical operators ([Table I](#T0001){ref-type="table"}). The Cochrane Database of Systematic Reviews, DARE, PubMed and EMBASE databases were also searched for review articles. In addition, the Cochrane IBD/FBD Review Group Specialized Trials Register and websites of the British Society of Gastroenterology and European Crohn\'s and Colitis Organization were searched for relevant information concerning the clinical trials. Registers of controlled trials ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) were searched for unpublished or ongoing trials. Reference lists from potentially relevant papers were hand-searched in order to identify additional studies.

###### 

MeSH subject headings and EMTREE keywords used in constructed search strategy for primary studies (last updated: 22.11.2012)

  Key words (combined with Boole\'s logical operator, OR)   
  --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medical condition                                         Crohn disease OR Crohn\'s disease OR Crohns disease OR Ileocolitis OR Ileitis, Terminal OR Ileitis, regional OR Colitis, granulomatous OR Enteritis, granulomatous OR Enteritis, regional OR Enteritis regionalis OR Regional enterocolitis OR Morbus Crohn OR Cleron disease
  **Intervention**                                          Infliximab OR Remicade OR Revellex OR Avakine OR Monoclonal antibody cA2 OR MAb cA2 OR Schering-Plough brand of infliximab OR Schering brand of infliximab OR Centocor brand of infliximab OR Essex brand of infliximab
                                                            Adalimumab OR Humira OR trudexa OR D2E7 antibody OR Abbott brand of adalimumab Certolizumab OR Cimzia OR CDP870 OR CDP 870 OR UCB Pharma brand of certolizumab pegol OR Pegylated tumor necrosis factor alpha antibody Fab fragment OR pha 738144 OR pha738144
  **Methodological limits**                                 **PubMed:** Humans, Randomized Controlled Trial, Clinical Trials, Controlled Clinical Trial **EMBASE:** Humans, Controlled Clinical Trials, Randomized Controlled Trial, Embase only **CENTRAL:** No limits applied; word variations have been searched
  **Language limits**                                       **PubMed**, **EMBASE:** English, French, German, Polish

The methods of the systematic reviews were applied as described in the Cochrane Handbook \[[@CIT0004]\], and the report was prepared according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines \[[@CIT0005]\]. The search and selection of the trials that were included were conducted by two reviewers independently. All of the potentially relevant articles were retained and their full text was critically reviewed according to the predefined inclusion or exclusion criteria. Data extraction was performed by a single reviewer using a standard data extraction form, before being then checked by a second reviewer. For the included studies, information was extracted on study design, severity of disease, dosage and scheme of the administered anti-TNF-α agents, duration of treatment and clinical outcomes. The methodological quality of each of the trials included was assessed independently by two reviewers. Randomized clinical trials (RCTs) included in the present review were evaluated using the Jadad scale \[[@CIT0006]\], and the CCT was assessed using the Newcastle-Ottawa Scale (NOS) \[[@CIT0007]\].

The outcome measures reported in the selected studies were based mainly on changes in the Crohn\'s Disease Activity Index (CDAI) and included: clinical response defined as a reduction of ≥70 points (CR-70) or of ≥100 points (CR-100) from the baseline in the CDAI score, and clinical remission defined as a decrease in the CDAI score of ≤ 150 points from baseline. Safety profile was also assessed.

Statistical analysis {#S20003}
--------------------

For dichotomous data, the impact of the intervention was expressed as a relative benefit -- RB (described as risk ratio (RR) on the graphs presented due to specific labeling of the effect measurement in the statistical analysis software) with 95% confidence intervals (CI). Adverse events were summarized with RR (relative risk). The results obtained from separate trials were combined using appropriate meta-analysis methods. The inverse variance, Mantel-Haenszel or Der Simonian-Laird effects model was used according to the data input and heterogeneity test results. The results were pooled for sufficiently similar outcomes and homogeneous data (determined by the degree of clinical and statistical heterogeneity). The clinical heterogeneity was assessed by examining the characteristics of the featured studies, whereas the statistical heterogeneity was assessed using the χ^2^ test, with the significance regarded as a *p* value =0.10. Relative parameters were calculated using a fixed effects model when the statistical heterogeneity was not detected, and a random effects model was used when heterogeneity was present. In all of the analyses RevMan 5.1.0 was used.

Results {#S0004}
=======

Systematic review {#S20005}
-----------------

The initial search identified 1072 citations, 1025 of which were excluded after examining the titles and abstracts. A further performed selection resulted in the identification of 47 potentially eligible studies. A total of 28 articles were excluded for various reasons, and 18 RCTs and 1 CCT fulfilled the inclusion criteria ([Figure 1](#F0001){ref-type="fig"}). In addition, 45 ongoing trials of infliximab, adalimumab or certolizumab were identified at [www.clinicaltrials.gov](http://www.clinicaltrials.gov), although they did not meet the inclusion criteria.

![PRISMA flow diagram for selection of studies identified in the systematic review](AMS-9-21672-g001){#F0001}

The studies included two trial designs: induction therapy and maintenance therapy, in both populations of adult patients: moderate to severe, predominantly or wholly non-fistulizing CD and fistulizing disease. All the studies were published in English as peer-reviewed articles. Among the five included randomized controlled trials comparing infliximab with placebo, 3 RCTs were conducted in patients with non-fistulizing Crohn\'s disease for induction treatment. The characteristics and the methodological quality of the trials included are described in [Table II](#T0002){ref-type="table"}.

###### 

Methodological quality of included RCTs and CCT

  Study                            The Jadad scores   Allocation concealment                               
  -------------------------------- ------------------ ------------------------ --- --------------- --- --- ---------
  \[[@CIT0009]\] Targan 1997       1                  0                        1   1               1   4   Yes
  \[[@CIT0010]\] Rutgeerts 1999    1                  0                        1   0               1   3   Yes
  \[[@CIT0011]\] Hanauer 2002      1                  0                        1   0               1   3   Yes
  \[[@CIT0012]\] Sands 2004        1                  0                        1   0               1   3   Unclear
  \[[@CIT0013]\] Present 1999      1                  0                        1   1               1   4   Yes
  \[[@CIT0014]\] Hanauer 2006      1                  0                        1   0               1   3   Yes
  \[[@CIT0015]\] Sandborn 2007     1                  0                        1   0               1   3   Yes
  \[[@CIT0016]\] Sandborn 2007     1                  0                        1   0               1   3   Yes
  \[[@CIT0017]\] Colombel 2007     1                  0                        1   0               1   3   Yes
  \[[@CIT0018]\] Rutgeerts 2012    1                  0                        1   0               0   2   Unclear
  \[[@CIT0019]\] Watanabe 2012     1                  0                        1   0               1   3   Unclear
  \[[@CIT0020]\] Winter 2004       1                  0                        1   0               1   3   Unclear
  \[[@CIT0021]\] Schreiber 2005    1                  0                        1   0               1   3   Unclear
  \[[@CIT0022]\] Sandborn 2011     1                  0                        1   0               0   2   Unclear
  \[[@CIT0023]\] Sandborn 2007     1                  0                        1   0               1   3   Yes
  \[[@CIT0024]\] Schreiber 2007,   1                  0                        1   0               1   3   Yes
  \[[@CIT0025]\] Schreiber 2011                                                                            
  \[[@CIT0026]\] Van Assche 2012   1                  0                        0   0               1   2   Yes
  Study                                                                            The NOS score           
  \[[@CIT0027]\] Riis 2012                                                         Good quality            

1 -- Was the study described as randomized?; 2 -- Was the method of randomization described and appropriate?; 3 -- Was the study described as double blind?; 4 -- Was the method of blinding described and appropriate?; 5 -- Were withdrawals and dropouts described? Additional explanation: question 2 has been scored 0 in case of lack of any description or when the method of randomization used in the study was other than simple; question 4 has been scored 0 in case of lack of any description of blinding or when the presented description was not detailed

Each of the studies included had a parallel group design and almost all of the RCTs were conducted with double blinding. A majority of the randomized studies scored ≥ 3 points on the Jadad scale, indicating good methodological quality, except for study \[[@CIT0026]\] which scored two points due to its open-label design, and studies \[[@CIT0018], [@CIT0022]\] due to a lack of description of withdrawals and dropouts. Six of the studies did not provide information on allocation concealment ([Table III](#T0003){ref-type="table"}).

###### 

Characteristics of included studies

  Study author and year of publication; design; sites          Population; severity of CD                                                                                                *N* (for efficacy)                                                                                                                                                                   Dosage and schedule, duration of treatment and follow-up                                                                                                                                                                                                                                                             Outcomes and point at which extracted
  ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Infliximab vs. placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  \[[@CIT0009]\] Targan 1997; RCT; 18 sites                    Moderate-to-severe Crohn\'s disease                                                                                       Placebo, *n* = 25; infliximab 5 mg, *n* = 27; 10 mg, *n* = 28; 20 mg, *n* = 28                                                                                                       **Induction:** placebo or infliximab 5 mg/kg; 10 mg/kg, or 20 mg/kg at week 0 (to week 12)                                                                                                                                                                                                                           Remission: CDAI \< 150 at weeks 4 and 12
  \[[@CIT0010]\] Rutgeerts 1999; RCT; 17 sites                 Crohn\'s disease and clinical response to initial treatment in previous study \[[@CIT0009]\]                              Placebo, *n* = 36; infliximab, *n* = 27                                                                                                                                              **Maintenance:** initial response to placebo or infliximab (Targan), then at week 12 randomization to placebo or infliximab 10 mg/kg, at 8-weekly intervals thereafter (to week 48)                                                                                                                                  Remission: CDAI ≤ 150 at week 48
  \[[@CIT0011]\] Hanauer 2002, ACCENT I; RCT; 55 sites         Moderate-to-severe Crohn\'s disease                                                                                       Randomized as responders at week 2: placebo, *n* = 110; infliximab 5 mg, *n* = 113; infliximab 5 and 10 mg, *n* = 112                                                                **Maintenance:** initial response to open-label infliximab 5 mg/kg, then randomization to placebo or infliximab 5 mg/kg at weeks 2 and 6 or infliximab 5 mg/kg at weeks 2 and 6 followed by 10 mg/kg at 8-weekly intervals thereafter (to week 46). Note: both infliximab groups received 5 mg/kg at weeks 2 and 6   Remission: CDAI ≤ 150 at week 54 (for '2-week' responders)
  \[[@CIT0012]\] Sands 2004, ACCENT II, RCT; 45 sites          Crohn\'s disease and ≥ 1 draining abdominal or perianal fistulas of ≥ 3 months' duration                                  Randomized responders, *n* = 195: placebo, *n* = 99; infliximab, *n* = 96                                                                                                            **Maintenance:** infliximab 5 mg/kg at weeks 0, 2 and 6 for all patients; at week 14 responders (*n* = 195) and non-responders (*n* = 87) were randomized to placebo or infliximab 5 mg/kg at 8-weekly intervals thereafter (to week 54)                                                                             Absence of any draining fistulas or reduction ≥ 50% in the number of draining fistulas at week 54 (for responders)
  \[[@CIT0013]\] Present 1999; RCT; 12 sites                   Crohn\'s disease and draining abdominal or perianal fistulas of ≥ 3 months' duration                                      Placebo, *n* = 31; infliximab 5 mg, *n* = 31; 10 mg, *n* = 32                                                                                                                        **Induction:** placebo or infliximab 5 mg/kg or 10 mg/kg at weeks 0, 2 and 6 (to week 18)                                                                                                                                                                                                                            Absence of any draining fistulas or reduction ≥ 50% in the number of draining fistulas at week 18
  **Adalimumab vs. placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  \[[@CIT0014]\] Hanauer 2006, CLASSIC I; RCT; 55 sites        Moderate-tosevere Crohn\'sdisease                                                                                         Placebo, *n* = 74; adalimumab 40/20 mg, *n* = 74, 80/40 mg, *n* = 75, 160/80 mg, *n* = 76                                                                                            **Induction:** placebo or adalimumab: 40 mg/20 mg, 80 mg/40 mg or 160 mg/80 mg at week 0/2 (to week 4)                                                                                                                                                                                                               Remission: CDAI \< 150at week 4
  \[[@CIT0015]\] Sandborn 2007, GAIN; RCT; 52 sites            Moderate-to-severe Crohn\'s disease for ≥ 4 months, after previous infliximab                                             Placebo, *n* = 166; adalimumab, *n* = 159                                                                                                                                            **Induction:** placebo or adalimumab 160/80 mg at week 0/2 (to week 4)                                                                                                                                                                                                                                               Remission: CDAI \< 150 at week 4. Response: decrease in CDAI score of \> 70 or \> 100 points at week 4
  \[[@CIT0016]\] Sandborn 2007, CLASSIC II; RCT; 53 sites      As above; 55 patients in remission at week 0 (week 4 of CLASSIC I)                                                        Placebo, *n* = 18; adalimumab 40 mg every other week, *n* = 19; adalimumab 40 mg weekly, *n* = 18                                                                                    **Maintenance:** initial adalimumab or placebo as part of study CLASSIC-I, then remission after open-label adalimumab 40 mg (week 0 (week 4 of CLASSIC I) and 2), then randomization to placebo or adalimumab 40 mg weekly or 40 mg every other week (to week 56)                                                    Remission: CDAI ≤ 150 at 56 weeks. Response: decrease in CDAI score of \> 70 or \> 100 points at week 56 (from week 0 in CLASSIC I)
  \[[@CIT0017]\] Colombel 2007, CHARM; RCT, 92 sites           Moderate-to-severe, active Crohn\'s disease, also with draining fistulas                                                  Randomized responders: placebo, *n* = 170; adalimumab 40 mg every other week, *n* = 172; adalimumab 40 mg weekly, *n* = 157 with fistulas: placebo, *n* = 47; adalimumab, *n* = 70   **Maintenance:** initial response to open-label adalimumab 80/40 mg (week 0/2); at week 4 randomization to placebo or adalimumab 40 mg weekly or 40 mg every other week (to week 56)                                                                                                                                 Remission: CDAI \< 150 at weeks 26 and 56 (for responders). Response: decrease in CDAI score of \> 70 or \> 100 points at weeks 25 and 56. Complete fistula healing
  \[[@CIT0018]\] Rutgeerts 2012, EXTEND; RCT; 19 sites         Moderate-to-severe Crohn\'s disease for ≥ 4 months and presence of mucosal ulceration, also with fistulas (12%)           Placebo, *n* = 65; adalimumab, *n* = 64                                                                                                                                              **Maintenance:** initial response to open-label adalimumab 160/80 mg at week 0/2; at week 4 randomization to placebo or adalimumab 40 mg every other week (to week 52). Note: maintenance without preselection for a response to induction but randomization stratified by CR-70 status at week 4                    Remission: CDAI \< 150 at weeks 12 and 52. Response: decrease in CDAI score of \> 70 or \> 100 points at weeks 12 and 52
  \[[@CIT0019]\] Watanabe 2012; RCT; multicentre               Moderate-to-severe, active Crohn\'s disease for ≥ 4 months                                                                Induction: placebo, *n* = 23; adalimumab 160/80 mg, *n* = 33; 80/40 mg, *n* = 34                                                                                                     **Induction:** placebo or adalimumab 160/80 mg or adalimumab 80/40 mg at week 0/2 (to week 4)                                                                                                                                                                                                                        Remission: CDAI \< 150 at week 4. Response: decrease in CDAI score of \> 70 or \> 100 points at week 2 and 4 (for patients with remission at week 2)
  Maintenance: placebo, *n* = 25; adalimumab 40 mg, *n* = 25   **Maintenance (responders only):** at week 4 randomization to placebo or adalimumab 40 mg every other week for 52 weeks   Remission: CDAI \< 150 at week 52. Response: as above, at week 52                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **Certolizumab vs. placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  \[[@CIT0020]\] Winter 2004; RCT; 24 sites                    Moderate to severe Crohn\'s disease                                                                                       Placebo, *n* = 24; certolizumab 1.25 mg, *n* = 2; 5 mg, *n* = 26; 10 mg, *n* = 17; 20 mg/kg, *n* = 23                                                                                **Induction:** placebo or certolizumab 5 mg/kg; 10 mg or 20 mg/kg at week 0 (followed to week 12)                                                                                                                                                                                                                    Remission: CDAI ≤ 150 at week 4. Response: decrease in CDAI score of ≥ 100 points at week 4
  \[[@CIT0021]\] Schreiber 2005; RCT; 58 sites                 Moderate to severe Crohn\'s disease                                                                                       Placebo, *n* = 73; certolizumab 100 mg, *n* = 74; 200 mg, *n* = 72; 400 mg, *n* = 72                                                                                                 **Induction:** placebo or certolizumab 100 mg, 200 mg or 400 mg at week 0 and further doses of the same medication at weeks 4 and 8                                                                                                                                                                                  Remission: CDAI ≤ 150 at week 12. Response: decrease in CDAI score of ≥ 100 points
  \[[@CIT0022]\] Sandborn 2011; RCT; 120 sites                 Moderate to severe Crohn\'s disease                                                                                       Placebo, *n* = 209; certolizumab, *n* = 215                                                                                                                                          **Induction:** placebo or certolizumab 400 mg at weeks 0, 2, and 4 (followed to week 6)                                                                                                                                                                                                                              Remission, CDAI ≤ 150 at weeks 2, 4 and 6. Response: decrease in CDAI score of ≥ 100 points at weeks 2, 4 and 6
  \[[@CIT0023]\] Sandborn 2007, PRECiSE I; RCT; 171 sites      Moderate to severe, active Crohn\'s disease for ≥ 3 months, also with fistulas                                            Placebo, *n* = 328; certolizumab, *n* = 331                                                                                                                                          **Short- and long-term induction:** placebo or certolizumab 400 mg at weeks 0, 2, and 4 and then every 4 weeks (to week 26). Note: treatment after week 4 without preselection for a response to induction                                                                                                           Remission: CDAI ≤ 150 at week 6 and 26. Response: decrease in CDAI score of ≥ 100 points at week 6 and 26 (and combined)
  \[[@CIT0024]\] Schreiber 2007, PRECiSE II; RCT; 147 sites    Moderate to severe, active Crohn\'s disease for ≥ 3 months                                                                Placebo, *n* = 210; certolizumab, *n* = 215                                                                                                                                          **Maintenance:** initial response to open label certolizumab at weeks 0, 2, and 4; at week 6 randomization to placebo or certolizu-mab 400 mg every 4 weeks (to week 24 and followed through week 26)                                                                                                                Remission: CDAI ≤ 150. Response: decrease in CDAI score of ≥ 100 points at week 26
  \[[@CIT0025]\] Schreiber 2011, PRECiSE II                    As above; subgroup of patients with draining fistulas at baseline                                                         Placebo, *n* = 30; certolizumab, *n* = 28                                                                                                                                            At week 6, responders with draining fistulas (*n* = 58) were randomized to placebo or certolizumab 400 mg every 4 weeks across weeks 8--24                                                                                                                                                                           Absence of any draining fistulas at week 26
  **Infliximab vs. adalimumab**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  \[[@CIT0026]\] Van Assche 2012, SWICH; RCT; single-centre    Crohn\'s disease and ongoing response to at least 6 months of maintenance infliximab                                      Infliximab, *n* = 37; adalimumab, *n* = 36                                                                                                                                           **Maintenance:** infliximab 5 mg/kg or adalimumab 80 mg at baseline followed by 40 mg every other week for 54 weeks                                                                                                                                                                                                  Dose intensification, early treatment termination, preferences, increase in the CDAI of \> 100 above baseline
  \[[@CIT0027]\] Riis 2012; retrospective, cohort study        Crohn\'s disease                                                                                                          Infliximab, *n* = 64; adalimumab, *n* = 19                                                                                                                                           Infliximab 5 mg/kg at weeks 0, 2 and 6 or adalimumab 80 mg at baseline followed by 40 mg every other week (up to median 11.4 months)                                                                                                                                                                                 Discontinuation of anti-TNF therapy, hospitalization and surgery rates

Efficacy analysis {#S20006}
-----------------

We performed a meta-analysis of eligible RCTs that compared infliximab, adalimumab and certolizumab (separately as subgroups and then together) with a placebo. In particular comparisons, combined doses of anti-TNF agents were used. The efficacy endpoints were: clinical remission at week 4 for short- and one long-term induction trials and separately at weeks 20--30, for studies evaluating the maintenance of remission after an open-label induction (primarily among responders) at weeks 48--56. Week 4 was chosen because in most of the induction studies the results were shown for that period, and because the placebo response and remission rates increased after 4 weeks in the induction studies \[[@CIT0008]\]. An evaluation of the clinical response (CR-70 or CR-100) was performed separately for both short- and long-term induction studies (with the data extracted at week 4) and for long-term maintenance studies (48--56 weeks, one study \[[@CIT0024]\] lasted only 26 weeks). For the fistulizing form of CD, the efficacy endpoints were closure of ≥ 50% of draining fistulas and complete fistula closure after ≥ 2 consecutive visits.

### Induction of remission at week 4

Eight trials assessing the efficacy of the three anti-TNF agents for short-term induction of remission were included: seven short-term trials \[[@CIT0009], [@CIT0014], [@CIT0015], [@CIT0019]--[@CIT0022]\] and one long-term induction trial \[[@CIT0023]\]. We included the Winter *et al*. 2004 \[[@CIT0020]\] study, although certolizumab was administered not subcutaneously but intravenously. Finally, it turned out that this way of administering certolizumab did not affect the results. The overall analysis revealed that the anti-TNF therapy was significantly more effective than placebo for induction of remission at week 4 (RB = 1.90, 95% CI: 1.55--2.33, *p* \< 0.00001). Results of the analysis in subgroups have shown that the probability of remission was significantly higher for both adalimumab and certolizumab when compared to the placebo ([Figure 2](#F0002){ref-type="fig"}). A subgroup analysis could not be performed for infliximab because only one study was available for this endpoint.

![The effect of anti-TNF agents compared with placebo on induction of remission at week 4](AMS-9-21672-g002){#F0002}

#### Maintenance of remission after open-label induction

Seven trials that evaluated maintenance of infliximab \[[@CIT0010], [@CIT0011]\], adalimumab \[[@CIT0016]--[@CIT0019]\] and certolizumab \[[@CIT0023], [@CIT0024]\] were included in the evaluation of maintenance of remission among responders after open-label induction (except for study \[[@CIT0018]\] where patients underwent maintenance treatment irrespective of the response to the previous induction phase). In the overall analysis the anti-TNF therapy was significantly more effective than the placebo for the maintenance of remission at weeks 48--56 (RB = 2.75, 95% CI: 2.13--3.54, *p* \< 0.00001). In the subgroup analysis there were also significant benefits in favor of infliximab and adalimumab ([Figure 3](#F0003){ref-type="fig"}). The inclusion of the certolizumab results from study \[[@CIT0024]\] did not affect the overall efficacy of the anti-TNF therapy for the maintenance of remission (RB = 2.30, 95% CI: 1.73--3.06, *p* \< 0.00001). The results of subgroups (infliximab vs. placebo RB = 2.00, 95% CI: 1.44--2.77, *p* \< 0.0001; adalimumab vs. placebo RB = 2.24, 95% CI: 1.69--2.98, *p* \< 0.00001; certolizumab vs. placebo RB = 1.64, 95% CI: 1.36--1.99, *p* \< 0.00001) and the results of the overall meta-analysis (RB = 1.86, 95% CI: 1.61--2.15, *p* \< 0.00001) for the maintenance of remission at weeks 20--30 (including study \[[@CIT0023]\] with randomization before the induction) show that each of the three anti-TNF agents was significantly more effective than the placebo.

![The effect of anti-TNF agents compared with placebo on maintenance of remission at week 48--56 (excluding study \[[@CIT0024]\])](AMS-9-21672-g003){#F0003}

#### Rates of fistula closure

Seven studies evaluated the anti-TNF agents for the treatment of fistulizing CD, although only 2 of the trials were designed specifically to address this issue \[[@CIT0012], [@CIT0013]\]. During short-term induction treatment with infliximab \[[@CIT0013]\] and adalimumab \[[@CIT0014], [@CIT0015]\] significantly more patients achieved a ≥ 50% reduction in fistulas in comparison with the placebo (RB = 1.70, 95% CI: 1.03--2.82, *p* = 0.04). Similarly, in the long-term maintenance, both infliximab \[[@CIT0012]\] and certolizumab \[[@CIT0025]\] were associated with significantly greater rates for ≥ 50% fistula closure in the reported follow-up (RB = 1.84, 95% CI: 1.26--2.67, *p* = 0.001). When evaluating complete fistula closure, we also took into account the data from the short- and long-term induction trial \[[@CIT0023]\]. In the short-term induction therapy, combined infliximab \[[@CIT0013]\] and adalimumab \[[@CIT0014], [@CIT0015]\] were superior to the placebo in the complete healing of fistulas (RB = 2.44, 95% CI: 1.13--5.28, *p* = 0.02). Likewise, there was a statistically significant benefit of combined infliximab \[[@CIT0012]\], adalimumab \[[@CIT0017]\] and certolizumab \[[@CIT0025]\] over the placebo for complete fistula closure during the maintenance treatment (RB = 2.03, 95% CI: 1.38--2.98, *p* = 0.0003). No significant difference was detected in the rates of complete fistula healing in the short- and long-term induction trial \[[@CIT0023]\] (RB = 1.02, 95% CI: 0.58--1.82, *p* = 0.94) ([Figure 4](#F0004){ref-type="fig"}).

![The effect of anti-TNF agents compared with placebo on complete fistula closure](AMS-9-21672-g004){#F0004}

#### Induction of response (70-CR and 100-CR) at week 4

Data on the clinical response rate defined as 70-CR or 100-CR in the CDAI score at week 4 of short- and long-term induction trials were available and extracted from seven studies (one evaluating infliximab \[[@CIT0009]\] and three for both adalimumab \[[@CIT0014], [@CIT0015], [@CIT0019]\] and certolizumab \[[@CIT0020], [@CIT0022], [@CIT0023]\]). In the overall analysis the anti-TNF therapy was more effective than the placebo for achieving the clinical response described as 70-CR at week 4 (RB~fixed~ = 1.64, 95% CI: 1.37--1.95, *p* \< 0.00001). The subgroup analysis also favored infliximab and adalimumab but not the certolizumab used in the single eligible study \[[@CIT0023]\]. Data on the clinical response 100-CR at week 4 of the induction treatment was available in six trials. There were no data on infliximab and 100-CR at week 4. In the subgroup and overall analysis, there were no statistically significant differences between anti-TNF agents, both adalimumab and certolizumab versus placebo (RB = 1.21, 95% CI: 0.81--1.80, *p* = 0.35) ([Figure 5](#F0005){ref-type="fig"}).

![The effect of anti-TNF agents compared with placebo on clinical response at week 4; 100 -- CR](AMS-9-21672-g005){#F0005}

#### Clinical response (70-CR and 100-CR) during maintenance

Five trials evaluated the clinical response defined as 70-CR during the long-term maintenance treatment with infliximab \[[@CIT0010], [@CIT0011]\] and adalimumab \[[@CIT0016]--[@CIT0018]\]. There were no extractable data for certolizumab. The overall result of the meta-analysis demonstrated that the anti-TNF therapy was statistically beneficial when compared to the placebo in achieving 70-CR at weeks 48--56 (RB~random~ = 2.06, 95% CI: 1.32--3.23, *p* = 0.002). To assess the 100-CR rates, there were no data regarding infliximab, although a study evaluating certolizumab at week 26 was included \[[@CIT0024]\]. The anti-TNF therapy was associated with a significantly increased relative benefit of achieving response 100-CR during maintenance when compared to the placebo (RB = 2.03, 95% CI: 1.48--2.78, *p* \< 0.0001) ([Figure 6](#F0006){ref-type="fig"}). Excluding study \[[@CIT0024]\], in which the data were extracted at week 26, the final result remains statistically unaffected (RB = 2.21, 95% CI: 1.40--3.51, *p* \< 0.0001).

![The effect of anti-TNF agents compared with placebo on clinical response during maintenance; 100 -- CR (including study \[[@CIT0024]\])](AMS-9-21672-g006){#F0006}

The outcomes evaluated in 2 studies comparing infliximab and adalimumab with each other were different from those concerning placebo-controlled trials. In study \[[@CIT0026]\] the results for adalimumab therapy (after switching from infliximab) were statistically inferior when compared to the continued use of infliximab with regard to the need for dose intensification, risk of early treatment termination (RR = 0.34, 95% CI: 0.15--0.77, *p* = 0.01) and risk of treatment discontinuation due to loss of response or intolerance (RR = 0.10, 95% CI: 0.01--0.72, *p* = 0.02). Both important and inconsistent with the clinical results, significantly more patients preferred adalimumab over infliximab at most time points throughout the study. In the cohort study \[[@CIT0027]\] most of the presented results concerned combined data for infliximab and adalimumab but, contrary to study \[[@CIT0026]\], no statistically significant difference was detected between infliximab and adalimumab in the need for dose intensification (RR = 3.28, 95% CI: 0.45--23.95, *p* = 0.24).

Safety analysis {#S20012}
---------------

We analyzed the incidence of any adverse events (AEs) and serious adverse events (SAEs) both occurring as a result of the short-term induction therapy and separately, and incidence of AEs during the long-term maintenance, irrespective of the presence of fistula.

### All adverse events or serious adverse events during short-term induction therapy

In the overall analysis, there was no significant difference in the frequency of any AEs between anti-TNF therapy and the placebo (RR = 1.00, 95% CI: 0.90--1.12, *p* = 0.97) in the short-term induction treatment (range: 4--12 weeks \[[@CIT0009], [@CIT0013]--[@CIT0015], [@CIT0019]--[@CIT0022]\]). In the subgroup analysis, the differences between the anti-TNF agents and placebo were not significant either (infliximab vs. placebo RR = 1.19, 95% CI: 0.95--1.49, *p* = 0.12; adalimumab vs. placebo RR = 0.88, 95% CI: 0.75--1.03, *p* = 0.11; certolizumab vs. placebo RR = 1.06, 95% CI: 0.94--1.20, *p* = 0.32). The results of study \[[@CIT0023]\] were excluded from the abovementioned analysis because the follow-up time was up to 26 weeks, although in the end the inclusion of its results did not affect the overall effect (RR~fixed~ =1.00, 95% CI: 0.95--1.06, *p* = 0.91). The pooled relative risk of the occurrence of SAEs ([Figure 7](#F0007){ref-type="fig"}) during the short-term induction treatment (4--12 weeks \[[@CIT0015], [@CIT0019]--[@CIT0022]\], study \[[@CIT0023]\] excluded) indicated the lack of statistical difference between therapies with anti-TNF agents and the placebo (RR = 1.00, 95% CI: 0.62--1.63, *p* = 0.99). There were no data available for infliximab on this outcome. After the inclusion of study \[[@CIT0023]\] the risk was 1.20 (95% CI: 0.85--1.71, *p* = 0.30).

![The effect of anti-TNF agents compared with placebo on risk of serious adverse events during induction](AMS-9-21672-g007){#F0007}

### All adverse events or serious adverse events during long-term maintenance therapy

No statistically significant difference in the incidence of any AEs during the long-term maintenance therapy (48--56 weeks for \[[@CIT0010], [@CIT0012], [@CIT0016]--[@CIT0019]\], 26 weeks for the PRECISE II study \[[@CIT0024]\]) was detected with the anti-TNF agents when compared with the placebo (RR = 0.99, 95% CI: 0.93--1.05, *p* = 0.72). The overall result of the meta-analysis revealed a statistically significant difference in the frequency of SAEs during the maintenance therapy in favor of the anti-TNF agents over the placebo (RR = 0.70, 95% CI: 0.58--0.86, *p* = 0.0005) \[[@CIT0011], [@CIT0012], [@CIT0016]--[@CIT0019], [@CIT0024]\], mainly due to a significantly lower risk of SAEs in the subgroup analysis for adalimumab \[[@CIT0016]--[@CIT0019]\] ([Figure 8](#F0008){ref-type="fig"}). Using the data available from study \[[@CIT0026]\] as a basis, there was no statistically significant difference detected in the risk of any AEs related to the anti-TNF therapy with infliximab when compared to adalimumab (RR = 0.88, 95% CI: 0.69--1.12, *p* = 0.29).

![The effect of anti-TNF agents compared with placebo on risk of serious adverse events durning maintenance](AMS-9-21672-g008){#F0008}

Discussion {#S0015}
==========

According to our knowledge, this is the first meta-analysis of the anti-TNF therapy in moderate to severe CD, involving fistulizing patients, that includes infliximab, adalimumab and certolizumab. Both infliximab and adalimumab are indicated for moderate to severe CD in patients unresponsive to or intolerant of conventional treatments. Although certolizumab has also shown promising data in adults with CD and received approval from the US FDA, it has not yet been approved by the EMA for that indication.

There were a few limitations for this meta-analysis. First, there are differences in design between the included studies: various periods of treatment with different aims (induction, maintenance), using different doses of agents given at various intervals throughout the studies and irrespective of the concomitant therapy. It is important to note that we performed a meta-analysis for the different types of study design separately: short-term induction trials with randomization before induction, long-term maintenance trials with randomization of responding patients at weeks 2--6 after open-label induction treatment, and one long-term induction trial with randomization before induction. The same method was used for evaluating the effect of the anti-TNF agent on fistula healing. Due to the methodological procedure, the limitations, connected with the dissimilar design of the included studies and their duration, did not influence the reliability of the obtained results to a great extent. Both short- and long-term induction studies were used to evaluate clinical remission and response rates at week 4 (for all the induction trials these data were extractable, although some studies lasted up to 12 weeks). For the long-term maintenance studies, the follow-up periods varied between 48 and 56 weeks, with one study lasting only 26 weeks \[[@CIT0024]\], and the last point of the trial follow-up was used to extract the outcomes of the data wherever trial reporting allowed it (likewise for the safety analysis in both the induction and maintenance therapy). In this setting, we carried out an additional analysis based on extractable data on the maintenance of remission at 20--30 weeks, with regard to the study PRECISE II \[[@CIT0024]\]. Apart from pooling the results from studies of different anti-TNF agents, different doses and slightly different durations of therapy (except for the clinical outcomes at week 4), we performed subgroup analyses for each of the anti-TNF agents in order to investigate potential differences in their efficacy. The results of the maintenance trials were almost exclusively based on the subgroups of the 'responders', which were selected for the analysis or randomization at varying time points after an induction period, during which all the patients received the study drug. Separate results for non-responders are not reported here. What should be noted, including study \[[@CIT0018]\] for *the maintenance of remission after open-label induction* could bias the overall results, because for this efficacy endpoint we included studies evaluating the maintenance of remission among responders after open-label induction, while maintenance treatment in study \[[@CIT0018]\] was conducted among patients probably not strictly preselected for a response to induction treatment. Additionally, the meta-analysis included the GAIN study \[[@CIT0015]\], where adalimumab was given to patients who did not achieve a response to previous infliximab therapy, thus possibly leading to an underestimation of the real efficacy of the anti-TNF agents in this setting. In regards to evaluation of the treatment effects on fistula healing, except data from two trials designed specifically to address this issue \[[@CIT0012], [@CIT0013]\], we extracted well-defined data on fistula closure from other primary studies also including patients with fistulizing disease, but it should be noted that patients included in the studies \[[@CIT0012], [@CIT0013]\] have more severe CD compared to all other studies included in this comparison, in which patients had moderately to severely active CD, defined as a CDAI score between 220 and 450. What is important, individual results from studies designed with healing of fistulas as the primary outcome of interest demonstrated a clear, statistically significant benefit of infliximab as well as adalimumab over placebo, even in more severe disease \[[@CIT0012], [@CIT0013]\]. Nevertheless, even after taking into consideration the results of this particular study there should be no difference in the reliability and statistical significance of the final results of the meta-analysis.

We identified two studies regarding a head-to-head comparison between infliximab and adalimumab \[[@CIT0026], [@CIT0027]\] in treatment for CD, but taking into consideration the differences in their methodology and quality, pooling the results was not recommended and a narrative synthesis was performed instead.

Several meta-analyses have shown the efficacy of anti-TNF therapy for inducing and maintaining clinical response and remission in patients with CD. It is a fact that these meta-analyses and reviews were performed with less contemporaneous research data and did not therefore consider the most recent studies published in 2011 and 2012. Peyrin-Biroulet *et al*. \[[@CIT0028]\] performed a meta-analysis comparing the effectiveness of six anti-TNF agents (infliximab, adalimumab, certolizumab, etanercept, onercept, and CDP571) with a placebo for induction and maintenance, steroid-sparing and fistula closure in CD. The methods of conducting that analysis were similar to ours. Based on 21 trials of which 16 were included in the efficacy analysis, there was evidence that the anti-TNF therapy is effective in patients with CD refractory to standard medical therapy, but the authors stated that the efficacy of the anti-TNF agents besides infliximab in the treatment of fistulizing patients requires additional investigation. Safety analyses revealed that the anti-TNF therapy does not increase the risk of death, serious infection or malignancy. However, subgroup analyses were performed, and the results of the overall meta-analysis also contain particular data from studies evaluating an anti-TNF agent other than antibodies (etanercept or onercept). The results of review \[[@CIT0029]\] showed the superiority of infliximab, adalimumab and certolizumab (separately) in relation to the placebo for the maintenance of remission in patients who have responded to prior induction therapy, but only infliximab was effective for the maintenance of fistula healing. The review also has two drawbacks. Firstly, it encompasses a small number of studies: three concerning infliximab, then two and one examining adalimumab and certolizumab, respectively. Secondly, the pooled results consisted of data from no more than two studies. This was caused by the fact that no overall (all anti-TNF agents combined) meta-analysis was performed. Results from 11 trials included in a more recent systematic review \[[@CIT0030]\] showed that both infliximab and adalimumab were beneficial for induction and maintenance therapy in adults with moderate to severe CD, and infliximab only for adults with a fistula when compared to a placebo. Certolizumab was not assessed. It also needs to be highlighted that the data from studies included in review \[[@CIT0030]\] were not pooled in the meta-analysis, and, for that reason, the conclusion from that descriptive analysis should be interpreted cautiously. In review \[[@CIT0031]\] there is an assessment of biological therapies (three anti-TNF antibodies and anti-integrin antibody) for Crohn\'s disease and ulcerative colitis (UC) treatment. In the overall analysis, the anti-TNF agents (certolizumab, adalimumab, and infliximab combined) were significantly more effective than the placebo for inducing remission and preventing relapse of CD, although the pooled data from six studies demonstrated no statistically significant difference in regard to healing of fistulizing CD. In review \[[@CIT0031]\], as described in the data extraction methodology, the data concerning the outcomes were extracted at the last point of the trial follow-up. It means that, as opposed to our analysis, the data for the induction of remission were extracted at different time points due to the fact that the eligible time of outcome assessment for induction trials was up to 4 months (note that induction therapy in study \[[@CIT0023]\] lasted 26 weeks). In addition, the combined result for fistula healing was presented without explanation of its definition (complete or partial closure). Our results on induction of remission or clinical response at week 4 are contrary to results obtained in the meta-analysis by Rahimi *et al*., 2011 \[[@CIT0032]\]. That meta-analysis included studies in which patients with CD were exposed to any therapeutic dosage of any anti-TNF agents (infliximab, certolizumab, CDP870, CDP571, etanercept, onercept) and shared some trials included in the current analysis. The results demonstrated that anti-TNF agents have no statistically significant effects on induction of remission after 2 weeks of treatment as well as clinical response and remission after 4 weeks. The only statistically significant benefit of anti-TNF agents over the placebo was observed for improving clinical response after 2 weeks of treatment. What is important, relevant data included in meta-analysis \[[@CIT0032]\] were collected up to December 2005. On the other hand, results from a meta-analysis including studies concerning severe ulcerative colitis \[[@CIT0033]\] showed that infliximab was significantly more beneficial than placebo for induction of remission at 2--8 weeks and slightly, but not significantly better than corticosteroids in regards to the induction of clinical remission up to week 13.

Fistulas, one of the most severe complications of CD, causes impairment in the quality of life and increase the likelihood of total colectomy. Perianal fistula is the most common fistula type, occurring in 25--50% of patients with CD \[[@CIT0012], [@CIT0025]\]. As mentioned above, some meta-analyses of anti-TNF antibodies have shown success with their use in fistulizing CD, but it particularly concerns infliximab \[[@CIT0028]--[@CIT0030]\]. Apart from surgery, another method of fistula treatment is short-term therapy with antibiotics. In a review \[[@CIT0034]\] pooling of data showed that immunoregulators and antibiotics are significantly more effective than placebo for ≥ 50% as well as complete fistula closure in fistulizing CD. In recent years treatment with anti-TNF antibodies has significantly improved the management of CD as well as UC refractory to conventional therapies; nevertheless, there is still a large number of patients showing an evaluative and disabling course of disease who require surgery \[[@CIT0003]\]. Pre-operative use of biological therapy such as anti-TNF agents may potentially increase the risk for postoperative infectious complications by suppression of the immune response. In the meta-analysis performed by Ehteshami-Afshar *et al*., 2011 \[[@CIT0002]\], there was no evidence of significant differences in the rate of colectomy, post-colectomy infectious complications or deaths in patients with ulcerative colitis who received infliximab in comparison to those who did not. After pooling results from studies assessing UC and CD, the overall early post-operative complications were more frequent among patients who received infliximab pre-operatively (but not late post-operative complications). Nonetheless, the rate of post-operative hospitalization was significantly lower in patients with UC under infliximab therapy \[[@CIT0002]\].

Overall, anti-TNF therapy is a relatively safe treatment option in CD and other inflammatory bowel diseases \[[@CIT0001]\]. Results of our meta-analyses demonstrated no significant differences in the frequency of any adverse events, including serious AEs, between anti-TNF therapy and placebo during short-term treatment. Moreover, there was a significantly lower risk of SAEs during maintenance therapy in favor of anti-TNF agents over placebo.

The overall results of our meta-analysis indicated consistent superiority of the anti-TNF antibodies when compared to placebo in the induction and maintenance of clinical remission, but notably, in contrast to reviews \[[@CIT0028], [@CIT0031]\], we demonstrated their significant beneficial effect on fistula healing also in short-term induction therapy. What should be emphasized is that we took into consideration such outcomes as clinical response (CR-70, CR-100), which was evaluated separately for both short-term induction and maintenance therapy, and has not been meta-analyzed in any previous reviews, except for article \[[@CIT0029]\], where the attention was only on maintenance therapy in patients who had already had remission after induction therapy, and article \[[@CIT0032]\] concerning the short-term induction phase. In contrast to previous articles, our updated review mentions the newest studies evaluating two of the anti-TNF antibodies in comparison with each other.

With respect to previous review studies, our systematic review is the most up-to-date systematic review (including studies published in 2012) on the effect of anti-TNF antibodies in CD, which in its methodology followed the methods described in the Cochrane Handbook, with the report having been prepared according to the PRISMA statement.

In conclusion, in general, the results of the meta-analysis demonstrated that anti-TNF therapy has a beneficial effect on induction and maintenance of clinical remission and response, as well as fistula healing, when compared with placebo. Based on a safety analysis, there was no evidence for an increase in the incidence of any adverse events related to anti-TNF when compared with placebo. In conclusion, the risk-benefit ratio of therapy with infliximab, adalimumab or certolizumab in CD is therefore in favor of these agents.
